June 2023
Includes: AGM, What’s New with PROSTAID Calgary, Volunteers needed, Enzalutamide Ups Metastasis-Free Survival, Improving immune responses in PC, MRI Guided Biopsies, BPH research updates, and more!
May 2023
Includes: Increase in active surveillance, Future Directions in Imaging, Physician’s Advice for defusing Patient Anger, Transgender Women Screening Disparity, and more!
April 2023
Includes: Back to In-Person Meetings , Guest speaker Hal Eagletail, Evolution of Precision Medicine for PC, Plant-based Diets reduce PC progression by 50%, and more!
March 2023
Includes: Prostate Cancer ADT Increases Bone Fracture Risk, Testosterone Therapy, Improving Survival in Black Patients, Advanced Prostate Cancer on the rise, Cal Ripken Jr. on PC, and more!
February 2023
Includes: Guest speakers Drs. Rob Rutledge and Gabriela Ilie, Exercise, diet and weight management during cancer treatment, women play a role in prostate health, CSSN needs your guidance, and more!
January 2023
Includes: President’s Message, Contribute your Genetic Profile to Help Prostate Cancer Research, Ivermectin for Cancer Treatment, Improving Sexual Health of Couples, and more!
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
PROSTAID Calgary’s 2022 Pathfinder Award went to Dr. Geoffrey Gotto, who presented on new research and innovations in metastatic castration-sensitive prostate cancer (MCSPC) that is leading to longer survival and greater quality of life in prostate cancer patients who do combinations of treatments to combat the cancer.
November 2022
Includes: Hybrid meeting details, call for participants for new MRU study, 2022 Pathfinder Award recipient revealed, Stress can increase cancer mortality, PTSD in prostate cancer patients, and more!
October 2022
Includes: New meeting space and focus groups for next meeting, The Changing Landscape of Systemic Therapy, How to Read a Genomic Testing Report, Prognosis of prostate cancer patients improved, and more!
July 2022
Includes: PROSTAID 50/50 Fundraising Raffle, Membership Door Prize Winner Announced, iSTRIDE Research Study, Treatment of the Primary or Local Relapse in nmCRPC, CADTH Study Participants Needed, and more!